Last edition
News about
GSK Pharma to Procure Solar Power from CleanMax for its Plant at Nashik, Maharashtra
GlaxoSmithKline Pharmaceuticals (GSK Pharma) has approved a plan to procure 4.95 MWp of solar power for its Nashik plant from Clean Max Enviro Energy Solutions to increase the company’s renewable energy intake and cut down greenhouse gas emissions.
OrtoWell Hydraulic Distractor System Proven Safe and Effective in First Multi-Centre Clinical Study
OrtoWay-US Inc, the US-German MedTech innovator focused on spinal surgery tools for orthopedic vertebral separation, has announced the publication of the first prospective, multi-center clinical study evaluating its OrtoWell Distractor System – the world's first hydraulically powered vertebral distractor.
Biocon's API Facility in Visakhapatnam Receives Two Observations from the US FDA
Indian biopharmaceutical company Biocon Ltd disclosed that its active pharmaceutical ingredient (API) manufacturing site in Visakhapatnam, Andhra Pradesh, was issued two observations following a routine US Food and Drug Administration (FDA) inspection.
Glenmark Secures China's Approval For RYALTRIS
Glenmark Pharmaceuticals has received regulatory approval in China for RYALTRIS. Combining olopatadine hydrochloride and mometasone furoate, it offers dual-action relief from nasal symptoms, further strengthening Glenmark’s position as a global leader in respiratory innovation.
Insilico Medicine and Eli Lilly Expand Collaboration to Accelerate AI-Driven Drug Discovery
The partnership aims to combine Insilico’s advanced Pharma.AI platforms with Lilly’s deep expertise in disease biology and drug development to jointly discover and advance innovative therapies for unmet medical needs.
FDA Approves DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma
The US FDA has approved DARZALEX Faspro as the first treatment for adult patients with High-Risk Smoldering Multiple Myeloma (HR-SMM), marking a key milestone in addressing this early stage of the disease.
Organon Announces Agreement to Divest its JADA System for up to USD 465 Million to Laborie
Organon has entered into a definitive agreement to divest its JADA System to Laborie for up to USD 465 million. The deal aims to leverage Laborie’s expertise in medical technology to expand the reach of JADA, enhancing access to postpartum hemorrhage treatment for mothers worldwide.
Alembic Secures US FDA Approval for Migraine Treatment Autoinjector
The approved product is therapeutically equivalent to the reference-listed drug, Imitrex STATdose System, priorly marketed by GlaxoSmithKline.
Novartis Opens New California Plant to Boost Cancer Drug Production
Novartis has opened a new 10,000-square-foot manufacturing facility in Carlsbad, California, to produce advanced radioligand therapies (RLTs) for cancer treatment. These innovative therapies combine precision targeting with radioactive particles to attack cancer cells while minimizing damage to healthy tissue.
Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra in India
Under this agreement, Emcure becomes the first Indian company to hold exclusive rights for the distribution and commercialisation of the drug, expanding access to Novo Nordisk’s innovative semaglutide therapy for people living with overweight and obesity in the country.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy